Navigation Links
Birth cohort screening for hepatitis C is cost effective, could save thousands of lives each year

PHILADELPHIA, November 4, 2011 According to a new study being published early online in Annals of Internal Medicine, the flagship journal of the American College of Physicians, birth cohort screening for hepatitis C is cost effective in the primary care setting. A proactive screening strategy could identify over 800,000 currently unidentified cases, which could save many thousands of lives each year.

About 1.5 percent of the nation's population is infected with hepatitis C (HCV), a virus that can cause inflammation and permanent liver damage. The infection is most prevalent among people born from 1945 through 1965, and approximately 50 to 75 percent of those with HCV are unaware that they are infected. This is a problem because HCV progresses slowly, and the risk of serious complications increases as time passes. In 2005, HCV resulted in up to 13,000 deaths. Experts say that without changes to current case identification and treatment, deaths from HCV are projected to increase to 35,000 a year by 2030.

Currently, the Centers for Disease Control and Prevention (CDC) recommends antibody screening only of individuals with health or lifestyle indicators suggesting potential infection. These indicators include a history of injecting drugs, having a blood transfusion before 1992, or being a chronic hemodialysis patient. Low case identification may result from the difficulty of implementing risk-based screening given the limited time of primary care visits and unease in discussing behavioral risks.

Researchers sought to determine if proactively screening the birth cohort of people born from 1945 through 1965 for HCV would be cost effective in the primary care setting. They developed a computer model to analyze the cost effectiveness of four scenarios: 1) no screening or treatment; 2) risk-based screening and standard treatment (pegylated interferon and ribavirin); 3) birth cohort screening with standard treatment; 4) birth cohort screening with standard treatment for patients identified with hepatitis C genotype 2 or 3, and standard treatment plus a direct acting antiviral drug (DAA) for patients identified with genotype 1 disease (the most prevalent genotype in the U.S.).

The researchers found that compared to the current strategy of risk-based screening, birth cohort screening followed by standard treatment reduced deaths by 82,300 at a cost of $15,700 per quality adjusted life-year (QALY) gained. Incorporating DAA treatment to standard therapy when indicated would prevent approximately 121,000 deaths compared to risk-based screening at a cost of $35,000 per QALY gained.

"The important things to remember about birth cohort screening are that, first, the strategy would identify over 800,000 people with hepatitis C if it were fully implemented, and second, the strategy is at least as cost-effective as many routinely administered preventive practices such as breast cancer screening or colorectal screening," said David Rein, PhD, Principal Research Scientist, Public Health Research Department, NORC at the University of Chicago, and lead author of the study.


Contact: Angela Collom
American College of Physicians

Related medicine news :

1. True Signs of Autism May Not Appear Until 1st Birthday
2. UAB-led study shows simple steps could reduce stillbirths by up to 1 million
3. March of Dimes Provides $2.6 Million in New Funding for Preterm Birth Research
4. Experts call for acceleration of research and interventions for prematurity and stillbirth
5. Black Women at Higher Risk of Birth-Related Heart Problem
6. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
7. Successful treatment of periodontal disease lowered preterm birth incidences
8. Improving care for low-birth-weight infants
9. Treating Gum Disease May Thwart Preterm Births
10. Ford CEO Asks Nation to March to Prevent Preterm Birth
11. Amnesty International Urges Congress to Turn Attention to Needed Reforms on Maternal and Childbirth Care
Post Your Comments:
(Date:12/1/2015)... ... 01, 2015 , ... The workstation boundaries for imaging specialists ... Systems launches MED-TAB™ -- the world’s first portable DICOM-calibrated medical image display, debuting ... December 4, 2015. , MED-TAB is expected to change teleradiology because for ...
(Date:12/1/2015)... IL (PRWEB) , ... December 01, 2015 , ... ... keeping their independence is everything. That is why Hollister Incorporated has launched the ... to offer this next product in the VaPro touch free catheter portfolio,” said ...
(Date:12/1/2015)... ... December 01, 2015 , ... McLean, VA., ... awarded a fixed price per sprint agile development contract to support the National ... over five years, provides software engineering, infrastructure, as well as operations and sustainment ...
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 - ... to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic Show, ... Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture capitalist ...
(Date:12/1/2015)... ... December 01, 2015 , ... Dr. Arash ... Modern Man for 2015. , Angeleno Magazine is a division of Modern ... in 1994, Modern Luxury includes more than 50 magazine titles across 15 major ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... VIEJO, Calif. , Dec. 1, 2015 /PRNewswire/ ... the prevalence of symptoms for pseudobulbar affect (PBA), ... outbursts of laughing and/or crying resulting from certain ... use of antipsychotic medications in nursing home residents, ... Geriatric Psychiatry. The study showed that almost one ...
(Date:12/1/2015)... 1, 2015 ... of the  "2016 Shigella Testing Market: ... Competitive Strategies, Emerging Opportunities--US, Europe (France, ... to their offering. --> ... of the  "2016 Shigella Testing Market: ...
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
Breaking Medicine Technology: